Compare JPMorgan Equity Premium Income ETF (JEPI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.71 (market cap $45.55B), while Vertex Pharmaceuticals Incorporated trades at $508.92 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.8× JPMorgan Equity Premium Income ETF's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Equity Premium Income ETF for 56 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| JEPI | VRTX | |
|---|---|---|
Market Cap | $45.55B | $127.55B |
Volume | 3,820,809 | 1,487,944 |
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $557.96 |
52-Week Low | $55.29 | $407.37 |
Typical Hold Time | 56 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $56.45, down 0.16% with a bearish technical outlook. The ETF maintains consistent monthly dividend distributions, with recent payments of $0.37 in August and September 2026. Technical indicators show bearish momentum with selling pressure in moving averages, while oscillators remain neutral. The fund continues to attract income-focused investors seeking monthly payouts through its covered call strategy.
The outlook remains cautious given the bearish technical signals and market volatility. Income investors may find value in the consistent dividend stream, but capital appreciation potential appears limited in the current technical environment. Key risks include market direction sensitivity and interest rate impacts on income strategies.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
